BioPharma Clinical Trials
Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its submission to the Center for Drug Evaluation (C...
August 26, 2024 | News
CanariaBio Inc, a leading late-stage biotechnology company, announces the successful completion of enrollment of 88 patients in a randomized Phase 2 study ...
August 26, 2024 | News
AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has fully enrolled and completed dosing the last patient in a Phase 1 tria...
August 26, 2024 | News
Everest Medicines , a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeut...
August 22, 2024 | News
CARsgen Therapeutics Holdings Limited , a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors...
August 20, 2024 | News
Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") announced that the Center for Drug Evaluation (CDE) of C...
August 20, 2024 | News
Pfizer Inc. and BioNTech SE announced top-line results from their Phase 3 clinical trial to evaluate the companies’ combined mRNA vac...
August 19, 2024 | News
Highlights: First-in-human clinical trial for SOF-SKN™ and Sofra™ platform Efficient trial design with early results expected Le...
August 19, 2024 | News
Boston Immune Technologies and Therapeutics, Inc. (BITT), a clinical stage developer of novel tumor necrosis factor superfamily receptor (TNFSR) antagonist...
August 19, 2024 | News
Vimgreen Pharmaceuticals, a science-driven pharmaceutical company focused on the modulation of adenosine signaling, announced the completion of enrollment ...
August 16, 2024 | News
Leading Victorian healthcare network, Alfred Health, has extended its long-standing Oracle Health footprint with Oracle's Oncology electroni...
August 14, 2024 | News
Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel Nectin-4 targeting ADC (R&D code: 9MW2821)...
August 13, 2024 | News
Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company, announced positiv...
August 13, 2024 | News
Biosyngen is proud to announce that the U.S. Food and Drug Administration (FDA) has approved its BRG01, an EBV-specific CAR-T cell therapy, to proceed with...
August 13, 2024 | News
Most Read
Bio Jobs
News
Editor Picks